AT Research Partners

AT RESEARCH PARTNERS is a collaboration between Anthony L. Dellinger and Terry E. Brady.

The Origination of Intellectual Property as a National Imperative

In the US, only 13% of PhD scientists and engineers have been awarded a first patent, and of those, rarely do they achieve a second patent. Notably, US STEM scholars are leaders in technology development and manufacturing engineering, yet domestic invention has been surpassed and overshadowed by foreign utility patents issued by the US Patent Office in recent years.  The domestic development and engineering talents thus have untapped potential that can readily advance protected technology into commerce.

AT Researcher Partners are pro se art originators working from the US and Caribbean. They have recognized vast opportunities in an array of sectors where disruptive innovation can provide global impact – and they have ensured patent protection and the commercialization potential it confers with each innovation. 

Beyond the listed inventions, AT Research Partners has focused intellectual property development primarily in:

• Cellular wellbeing 
• Congestive heart disease 
• Heart ablation 
• IV fluids, blood banking and plasma expanders. 
• Obesity (natural appetite appeasement – issued October 2023) 
• OTC oral health 
• Sustainable, clean energy 
• Tissue and organ viability for transplantation 
• Unassisted robotic surgery and atomic scale normothermic scalping

These initiatives are centered on intellectual property with respect to novelty and utility “due diligence” from the US Patent Office with each award that provides validation and protection.

AT Research Partners is seeking investment and development collaboration or IP divestiture with partners or investors seeking worthy technology with uncontested upside.